3rd Quarter - Report

ALEXION PHARMACEUTICALS, INC. for ALEXION PHARMACEUTICALS, INC.

Firm
Client
Income
—
Expenses
$275,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

EU FTA

LobbyistCovered position, as disclosed
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Comprehensive tax reform proposals Patent Box proposals Orphan Drug Tax Credit

LobbyistCovered position, as disclosed
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Health Issues HCR

ACA Implementation issues, including health exchanges and biosimilars Track & Trace; pharmaceutical compounding legislation 340B Issues Budget/Debt limit issues impacting Medicare, Medicaid, the FDA and federal health systems

LobbyistCovered position, as disclosed
VANESSA PROCTER —
HEIDI L WAGNER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.